J
Janak de Zoysa
Researcher at North Shore Hospital
Publications - 20
Citations - 943
Janak de Zoysa is an academic researcher from North Shore Hospital. The author has contributed to research in topics: Medicine & Renal function. The author has an hindex of 12, co-authored 16 publications receiving 684 citations. Previous affiliations of Janak de Zoysa include University of Queensland & Auckland City Hospital.
Papers
More filters
Journal ArticleDOI
Effects of Allopurinol on the Progression of Chronic Kidney Disease
Sunil V. Badve,Elaine M. Pascoe,Anushree Tiku,Neil Boudville,Fiona G. Brown,Alan Cass,Philip Clarke,Nicola Dalbeth,Richard O. Day,Janak de Zoysa,Bettina Douglas,Randall J. Faull,David Harris,Carmel M. Hawley,Graham R D Jones,John Kanellis,Suetonia C. Palmer,Vlado Perkovic,Gopala K. Rangan,Donna Reidlinger,Laura Robison,Robert J. Walker,Giles Walters,David W. Johnson,Ckd-Fix Study Investigators +24 more
TL;DR: In patients with chronic kidney disease and a high risk of progression, urate-lowering treatment with allopurinol did not slow the decline in eGFR as compared with placebo.
Journal ArticleDOI
Effects of uric acid-lowering therapy on renal outcomes: a systematic review and meta-analysis.
Bhadran Bose,Sunil V. Badve,Sunil V. Badve,Swapnil Hiremath,Neil Boudville,Neil Boudville,Fiona G. Brown,Fiona G. Brown,Alan Cass,Janak de Zoysa,Janak de Zoysa,Robert G. Fassett,Randall J Faull,Randall J Faull,David Harris,David Harris,Carmel M. Hawley,Carmel M. Hawley,John Kanellis,John Kanellis,Suetonia C. Palmer,Suetonia C. Palmer,Vlado Perkovic,Vlado Perkovic,Elaine M. Pascoe,Gopala K. Rangan,Gopala K. Rangan,Robert J. Walker,Robert J. Walker,Giles Walters,Giles Walters,David W. Johnson,David W. Johnson +32 more
TL;DR: Uric acid-lowering therapy with allopurinol may retard the progression of CKD, and adequately powered randomized trials are required to evaluate the benefits and risks of uric acid- Lowering therapy in CKD.
Journal ArticleDOI
A Novel Hypoxia-Inducible Factor−Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial
Richard A. Brigandi,Brendan M. Johnson,Coreen Oei,Mark Westerman,Gordana Olbina,Janak de Zoysa,Simon D. Roger,Manisha Sahay,Nicholas B Cross,Lawrence P. McMahon,Veerabhadra Guptha,Elena A. Smolyarchuk,Narinder Singh,Steven F. Russ,Sanjay Kumar,Alexey V. Borsukov,Vyacheslav V. Marasaev,Gullipalli Prasad,Galina Y. Timokhovskaya,Elena V. Kolmakova,Vladimir A. Dobronravov,Elena Zakharova,Georgi Abraham,David K. Packham,Dmitry A. Zateyshchikov,G P Arutyunov,Galina V. Volgina,Kirill S. Lipatov,Dmitry V. Perlin,Bruce A. Cooper,Tarun Kumar Saha,Olga A. Zagrebelnaya,Kalpana S. Mehta,Natalya A. Koziolova,Robert G. Fassett,Narina P. Alexeeva,Lidia V. Lysenko +36 more
TL;DR: GSK1278863 induced an effective EPO response and stimulated non-EPO mechanisms for erythropoiesis in anemic non-dialysis- dependent and dialysis-dependent patients with CKD.
Journal ArticleDOI
Antibacterial honey for the prevention of peritoneal-dialysis-related infections (HONEYPOT): a randomised trial
David W. Johnson,David W. Johnson,David W. Johnson,Sunil V. Badve,Sunil V. Badve,Elaine M. Pascoe,Elaine Beller,Alan Cass,Carolyn Clark,Janak de Zoysa,Janak de Zoysa,Nicole M. Isbel,Nicole M. Isbel,Steven McTaggart,Alicia T. Morrish,E. Geoffrey Playford,E. Geoffrey Playford,Anish Scaria,Paul Snelling,Paul Snelling,Liza A. Vergara,Carmel M. Hawley,Carmel M. Hawley +22 more
TL;DR: The findings of this trial show that honey cannot be recommended routinely for the prevention of peritoneal-dialysis-related infections.
Journal ArticleDOI
Predicting Outcome in Patients with Anti-GBM Glomerulonephritis.
Emma E. van Daalen,J. Charles Jennette,Stephen P. McAdoo,Charles D. Pusey,Marco A. Alba,Caroline J. Poulton,Ron Wolterbeek,Tri Q. Nguyen,Roel Goldschmeding,Bassam Alchi,Meryl Griffiths,Janak de Zoysa,Beula Vincent,Jan A. Bruijn,Ingeborg M. Bajema +14 more
TL;DR: In this paper, the authors identify clinical and histopathologic parameters that predict kidney outcome in patients with anti-glomerular basement membrane (anti-GBM) GN, and the 5-year kidney survival rate was 34%, with an improved rate observed among patients diagnosed after 2007.